Advertisement
Advertisement
REPL
Replimune Group, Inc.
5.30
USDSponsored
+1.21
+29.58%
May 13, 15:59 UTC -4
Closed
Pre-Market
5.37
+0.07
+1.23%
REPL Earnings Reports
Positive Surprise Ratio
REPL beat 16 of 31 last estimates.
52%
Next Report
Next Week
Date of Next Report
May 20, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.71
Implied change from Q3 26 (Revenue/ EPS)
--
/-7.79%
Implied change from Q4 25 (Revenue/ EPS)
--
/-13.41%
Replimune Group, Inc. earnings per share and revenue
On Feb 03, 2026, REPL reported earnings of -0.77 USD per share (EPS) for Q3 26, beating the estimate of -0.90 USD, resulting in a 15.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.81% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 9 analysts forecast an EPS of -0.71 USD, with revenue projected to reach -- USD, implying an decrease of -7.79% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Replimune Group, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Replimune Group, Inc. reported EPS of -$0.77, beating estimates by 15.18%, and revenue of $0.00, 0% as expectations.
How did the market react to Replimune Group, Inc.'s Q3 2026 earnings?
The stock price moved up 5.81%, changed from $6.97 before the earnings release to $7.38 the day after.
When is Replimune Group, Inc. expected to report next?
The next earning report is scheduled for May 20, 2026.
What are the forecasts for Replimune Group, Inc.'s next earnings report?
Based on 9
analysts, Replimune Group, Inc. is expected to report EPS of -$0.71 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement